Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress.

today announced two presentations at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, at Fira de Barcelona in ...

SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced ...

STOCKHOLM, May 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will present new clinical data and research outcomes at the annual European Congress of Rheumatology (EULAR 2025) in Barcelona from the ...

The EULAR 2024 - 2029 European Manifesto has already garnered support from multiple MEPs, who recognise the urgent need for action in addressing the challenges posed by RMDs, particularly in ...

Experts assembled by EULAR determined that most of the common medications for these conditions, including biologics, may be safely used during pregnancy and breastfeeding. The biggest concerns ...

nottingham.ac.uk The quality of the EULAR recommendations for the management of hip and knee osteoarthritis (OA) was evaluated using a validated instrument. The quality and methods were compared with ...

Additional information, including the accepted abstracts, can be accessed on the EULAR 2025 Congress website. Presentation materials will be made available in the Science section under Scientific ...